Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
orelabrutinib + pomalidomide + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone
- Development stage
- Unknown
- Lead developer
- First Affiliated Hospital of Soochow University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Pro-miniCHOP is a combination chemoimmunotherapy regimen consisting of orelabrutinib, pomalidomide, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. It is specifically designed for the treatment of treatment-naive elderly patients with diffuse large B-cell lymphoma (DLBCL). The regimen combines the "Pro" triplet—which includes the BTK inhibitor orelabrutinib, the immunomodulatory drug pomalidomide, and the anti-CD20 antibody rituximab—with a dose-reduced "miniCHOP" backbone. This approach aims to enhance therapeutic efficacy by targeting multiple oncogenic pathways and the tumor microenvironment while maintaining a manageable safety profile in an older patient population.
- Other names
- Pro-miniCHOP-like regimen
02
Targets
CD20 (B-lymphocyte antigen CD20)TOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)CRBN (Cereblon)DNATUBB (Tubulin (alpha and beta subunits))BTK (Bruton tyrosine kinase)
Beyond the preview
Go deeper on orelabrutinib + pomalidomide + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on orelabrutinib + pomalidomide + rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone.